These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34474563)

  • 1. Bi/Se-Based Nanotherapeutics Sensitize CT Image-Guided Stereotactic Body Radiotherapy through Reprogramming the Microenvironment of Hepatocellular Carcinoma.
    Liu J; Chen J; Liu H; Zhang K; Zeng Q; Yang S; Jiang Z; Zhang X; Chen T; Li D; Shan H
    ACS Appl Mater Interfaces; 2021 Sep; 13(36):42473-42485. PubMed ID: 34474563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A theranostic metallodrug modulates immunovascular crosstalk to combat immunosuppressive liver cancer.
    Luo Y; Wang J; Xu L; Du Q; Fang N; Wu H; Liu F; Hu L; Xu J; Hou J; Zhong Y; Liu Y; Wang Z; Ran H; Guo D
    Acta Biomater; 2022 Dec; 154():478-496. PubMed ID: 36280029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albumin-Templated Bi
    Yao Y; Li P; He J; Wang D; Hu J; Yang X
    ACS Appl Mater Interfaces; 2021 Jun; 13(24):28650-28661. PubMed ID: 34124895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast-enhanced ultrasound.
    Kamachi N; Nakano M; Okamura S; Niizeki T; Iwamoto H; Shimose S; Shirono T; Noda Y; Kuromatsu R; Koga H; Torimura T
    Cancer Rep (Hoboken); 2022 Feb; 5(2):e1471. PubMed ID: 34105904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. iRGD-mediated liposomal nanoplatforms for improving hepatocellular carcinoma targeted combination immunotherapy and monitoring tumor response
    Li J; Wei R; Yao W; Pang X; Wang N; Lai S; Wei X; Yuan Y; Jiang X; Yang R
    J Mater Chem B; 2024 Oct; 12(39):9963-9978. PubMed ID: 39189074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
    Ando Y; Kawaoka T; Suehiro Y; Yamaoka K; Kosaka Y; Uchikawa S; Kodama K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Azakami T; Takahashi S; Imamura M; Chayama K; Aikata H
    Oncology; 2020; 98(11):787-797. PubMed ID: 32882687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors.
    Une N; Takano-Kasuya M; Kitamura N; Ohta M; Inose T; Kato C; Nishimura R; Tada H; Miyagi S; Ishida T; Unno M; Kamei T; Gonda K
    Med Oncol; 2021 Apr; 38(6):60. PubMed ID: 33881631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
    Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
    World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
    Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S
    Oncology; 2020; 98(11):779-786. PubMed ID: 32877911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyaluronic acid-functionalized bismuth oxide nanoparticles for computed tomography imaging-guided radiotherapy of tumor.
    Du F; Lou J; Jiang R; Fang Z; Zhao X; Niu Y; Zou S; Zhang M; Gong A; Wu C
    Int J Nanomedicine; 2017; 12():5973-5992. PubMed ID: 28860761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.
    Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Koizumi Y; Hiasa Y; Michitaka K;
    Oncology; 2019; 97(6):334-340. PubMed ID: 31466068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced immunotherapy of SM5-1 in hepatocellular carcinoma by conjugating with gold nanoparticles and its in vivo bioluminescence tomographic evaluation.
    Ma X; Hui H; Jin Y; Dong D; Liang X; Yang X; Tan K; Dai Z; Cheng Z; Tian J
    Biomaterials; 2016 May; 87():46-56. PubMed ID: 26897539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib.
    Fujii Y; Ono A; Hayes CN; Aikata H; Yamauchi M; Uchikawa S; Kodama K; Teraoka Y; Fujino H; Nakahara T; Murakami E; Miki D; Okamoto W; Kawaoka T; Tsuge M; Imamura M; Chayama K
    J Exp Clin Cancer Res; 2021 Jun; 40(1):215. PubMed ID: 34174931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
    Yano S; Kawaoka T; Johira Y; Miura R; Kosaka M; Shirane Y; Murakami S; Amioka K; Naruto K; Ando Y; Kosaka Y; Yamaoka K; Kodama K; Uchikawa S; Fujino H; Ohno A; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Imamura M; Mori K; Arihiro K; Kuroda S; Kobayashi T; Ohdan H; Aikata H
    Medicine (Baltimore); 2021 Oct; 100(42):e27576. PubMed ID: 34678902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101.
    Bao X; Shen N; Lou Y; Yu H; Wang Y; Liu L; Tang Z; Chen X
    Theranostics; 2021; 11(12):5955-5969. PubMed ID: 33897892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
    Hoshi T; Watanabe Miyano S; Watanabe H; Sonobe RMK; Seki Y; Ohta E; Nomoto K; Matsui J; Funahashi Y
    Biochem Biophys Res Commun; 2019 May; 513(1):1-7. PubMed ID: 30944079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts.
    Tran A; Koh TS; Prawira A; Ho RZW; Le TBU; Vu TC; Hartano S; Teo XQ; Chen WC; Lee P; Thng CH; Huynh H
    Mol Imaging Biol; 2021 Feb; 23(1):70-83. PubMed ID: 32909245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A biocompatible theranostic agent based on stable bismuth nanoparticles for X-ray computed tomography/magnetic resonance imaging-guided enhanced chemo/photothermal/chemodynamic therapy for tumours.
    Zhao H; Wang J; Li X; Li Y; Li C; Wang X; Wang J; Guan S; Xu Y; Deng G; Chen Y; Lu J; Liu X
    J Colloid Interface Sci; 2021 Dec; 604():80-90. PubMed ID: 34265694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
    Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
    Torrens L; Montironi C; Puigvehí M; Mesropian A; Leslie J; Haber PK; Maeda M; Balaseviciute U; Willoughby CE; Abril-Fornaguera J; Piqué-Gili M; Torres-Martín M; Peix J; Geh D; Ramon-Gil E; Saberi B; Friedman SL; Mann DA; Sia D; Llovet JM
    Hepatology; 2021 Nov; 74(5):2652-2669. PubMed ID: 34157147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.